Similar articles

• Incidences of HBeAg and anti-HBe in, and clinical course of hepatitis B virus carriers.

  Tsuchie H, Kurimura O, Tamura I, Shimase K, Kaneto E, Kurimura T, Tsuda F, Mayumi M. Tsuchie H, et al. Biken J. 1984 Dec;27(4):169-76. Biken J. 1984. PMID: 6100353
• Evolution of HBeAg/anti-HBe status and its relationship to clinical and histological outcome in chronic HBV carriers in childhood.

  Sodeyama T, Kiyosawa K, Akahane Y, Tanaka E, Wada S, Oike Y, Nakamura M, Yoda H, Imai Y, Gibo Y, et al. Sodeyama T, et al. Am J Gastroenterol. 1986 Apr;81(4):239-45. Am J Gastroenterol. 1986. PMID: 3962948
• [HBeAg and anti-HBe in asymptomatic carriers of HBsAg and in various forms of hepatitis and liver cirrhosis].

  Kalinowska B, Nazarewicz-de Mezer T, Krawczyński K. Kalinowska B, et al. Przegl Epidemiol. 1984;38(3):249-56. Przegl Epidemiol. 1984. PMID: 6528039 Polish. No abstract available.
• [Precore region mutation in anti-HBe antibody positive asymptomatic healthy carriers].

  Fukuda R. Fukuda R. Nihon Rinsho. 1995 Oct;53 Suppl(Pt 2):189-94. Nihon Rinsho. 1995. PMID: 12442384 Review. Japanese. No abstract available.
• [Apoptosis and fulminant hepatitis].

  Sata M, Kumashiro R, Koga Y, Tanikawa K. Sata M, et al. Nihon Rinsho. 1995 Oct;53 Suppl(Pt 2):488-91. Nihon Rinsho. 1995. PMID: 12442432 Review. Japanese. No abstract available.